Trial · NCT06442748
Short Versus Long-term Levetiracetam in Brain Tumors
NCT06442748, Phase 3, Recruiting, Tata Memorial Centre
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Short Versus Long-term Levetiracetam in Brain Tumors. Trials, record NCT06442748. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06442748
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Short Versus Long-term Levetiracetam in Brain Tumors
- NCT number
- NCT06442748
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 604 participants, estimated
- Lead sponsor
- Tata Memorial Centre
- Conditions
- Seizures, Brain Tumors, Antiepileptics, Levetiracetam
- Interventions
- Levetiracetam
- First posted
- 2024-06-04
- Last updated
- 2026-02-13
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 2-year seizure free survival | 7 year | Seizure-free survival measured using Kaplan-Meier product limit method survival calculated from the time of randomization. |
| Secondary | Overall survival | 7 year | Overall survival calculated using Kaplan-Meier product-limit method. Death from any cause will be considered as an event. |
| Secondary | Progression-free survival | 7 year | Progression-free survival calculated using Kaplan-Meier product-limit method. Date of radiological progression will be considered as an event. |
| Secondary | Cost-benefit analysis Cost-benefit analysis | 7 year | Cumulative cost of antiepileptic medications and cost of management of seizures between the two groups will be compared using proportions of expenditure. |
| Secondary | Quality of life core questionnaire | 7 year | The European Organization for Research and Treatment of Cancer (EORTC) quality of life (QOL) core questionnaire (C30) will be used. The summary scores will be calculated from the raw scores as per the manual, ranging from 0 to 100, with higher scores representing better outcomes. The global score and scores of subdomains will be calculated during follow-up and compared with baseline. |
| Secondary | Quality of life brain cancer module | 7 year | The European Organization for Research and Treatment of Cancer (EORTC) brain module (BN20) questionnaire will be used. The summary scores will be calculated from the raw scores as per the manual, ranging from 0 to 100, with higher scores representing better outcomes. The global score and scores of subdomains will be calculated during follow-up and compared with baseline. |
| Secondary | Seizure-free survival between two arms using death as a competing risk | 7 years | Competing risk will be analyzed using Fine and Gray using death as a competing event for seizure. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers28
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06442748
GET https://conductscience.org/api/trials/v1/NCT06442748/papers?page=2